Mass Spectrometry-based Quantification of CYP Enzymes to Establish in Vitro/in Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2012 Feb 23

PMID 22354837

Citations 13

Authors

Aki T Heikkinen

Arno Friedlein

Jens Lamerz

Peter Jakob

Paul Cutler

Stephen Fowler

Tara Williamson

Roberto Tolando

Thierry Lave

Neil Parrott

Affiliations

Soon will be listed here.

Abstract

Purpose: Physiologically based models, when verified in pre-clinical species, optimally predict human pharmacokinetics. However, modeling of intestinal metabolism has been a gap. To establish in vitro/in vivo scaling factors for metabolism, the expression and activity of CYP enzymes were characterized in the intestine and liver of beagle dog.

Methods: Microsomal protein abundance in dog tissues was determined using testosterone-6β-hydroxylation and 7-hydroxycoumarin-glucuronidation as markers for microsomal protein recovery. Expressions of 7 CYP enzymes were estimated based on quantification of proteotypic tryptic peptides using multiple reaction monitoring mass spectrometry. CYP3A12 and CYP2B11 activity was evaluated using selective marker reactions.

Results: The geometric mean of total microsomal protein was 51 mg/g in liver and 13 mg/cm in intestine, without significant differences between intestinal segments. CYP3A12, followed by CYP2B11, were the most abundant CYP enzymes in intestine. Abundance and activity were higher in liver than intestine and declined from small intestine to colon.

Conclusions: CYP expression in dog liver and intestine was characterized, providing a basis for in vitro/in vivo scaling of intestinal and hepatic metabolism.

Citing Articles

Assessment of cytochrome P450 induction in canine intestinal organoid models.

Nagao I, Nakazawa M, Goyama T, Court M, Ambrosini Y Xenobiotica. 2024; 54(5):217-225.

PMID: 38441495 PMC: 11178462. DOI: 10.1080/00498254.2024.2326973.

Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome.

Harwood M, Zettl K, Weinheimer M, Pilla-Reddy V, Shen H, Jacobs F Mol Pharm. 2023; 20(7):3505-3518.

PMID: 37283406 PMC: 10324398. DOI: 10.1021/acs.molpharmaceut.3c00108.

Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Martinez M, Mochel J, Neuhoff S, Pade D AAPS J. 2021; 23(3):59.

PMID: 33907906 DOI: 10.1208/s12248-021-00590-0.

Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.

Doerksen M, Jones R, Coughtrie M, Collier A Eur J Drug Metab Pharmacokinet. 2020; 46(2):173-183.

PMID: 33340340 DOI: 10.1007/s13318-020-00666-w.

Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability.

Martinez S, Shi J, Zhu H, Perez Jimenez T, Zhu Z, Court M Drug Metab Dispos. 2019; 47(11):1314-1324.

PMID: 31427433 PMC: 6800445. DOI: 10.1124/dmd.119.088070.

References

Gertz M, Davis J, Harrison A, Houston J, Galetin A . Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab. 2008; 9(8):785-95. DOI: 10.2174/138920008786049276. View

Gertz M, Harrison A, Houston J, Galetin A . Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010; 38(7):1147-58. DOI: 10.1124/dmd.110.032649. View

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

Agger S, Marney L, Hoofnagle A . Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin Chem. 2010; 56(12):1804-13. PMC: 3103773. DOI: 10.1373/clinchem.2010.152264. View

Jones H, Parrott N, Ohlenbusch G, Lave T . Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet. 2006; 45(12):1213-26. DOI: 10.2165/00003088-200645120-00006. View

Kyokawa Y, Nishibe Y, Wakabayashi M, Harauchi T, Maruyama T, Baba T . Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact. 2001; 134(3):291-305. DOI: 10.1016/s0009-2797(01)00164-8. View

Baarnhielm C, Dahlback H, Skanberg I . In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol (Copenh). 1986; 59(2):113-22. DOI: 10.1111/j.1600-0773.1986.tb00142.x. View

Zhang Q, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky L . Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999; 27(7):804-9. View

Barter Z, Bayliss M, Beaune P, Boobis A, Carlile D, Edwards R . Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007; 8(1):33-45. DOI: 10.2174/138920007779315053. View

10.

Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K . Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008; 25(6):1469-83. DOI: 10.1007/s11095-008-9532-4. View

11.

Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, Terasaki T . Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci. 2010; 100(1):341-52. DOI: 10.1002/jps.22255. View

12.

Parrott N, Lukacova V, Fraczkiewicz G, Bolger M . Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. AAPS J. 2009; 11(1):45-53. PMC: 2664880. DOI: 10.1208/s12248-008-9079-7. View

13.

Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y . Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos. 2003; 31(9):1161-9. DOI: 10.1124/dmd.31.9.1161. View

14.

Nishibe Y, Wakabayashi M, Harauchi T, Ohno K . Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica. 1998; 28(6):549-57. DOI: 10.1080/004982598239308. View

15.

Barter Z, Chowdry J, Harlow J, Snawder J, Lipscomb J, Rostami-Hodjegan A . Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos. 2008; 36(12):2405-9. DOI: 10.1124/dmd.108.021311. View

16.

Perrett H, Barter Z, Jones B, Yamazaki H, Tucker G, Rostami-Hodjegan A . Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos. 2007; 35(10):1733-6. DOI: 10.1124/dmd.107.015743. View

17.

Yang J, Tucker G, Rostami-Hodjegan A . Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther. 2004; 76(4):391. DOI: 10.1016/j.clpt.2004.07.001. View

18.

Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R . A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys. 1995; 319(2):372-82. DOI: 10.1006/abbi.1995.1307. View

19.

Lange V, Picotti P, Domon B, Aebersold R . Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008; 4:222. PMC: 2583086. DOI: 10.1038/msb.2008.61. View

20.

Locuson C, Ethell B, Voice M, Lee D, Feenstra K . Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metab Dispos. 2008; 37(3):457-61. DOI: 10.1124/dmd.108.025312. View